Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2000

View Archived Issues

Immunomedics allowed patent for therapeutic vaccines

Alkermes and Glaxo Wellcome form pulmonary drug delivery collaboration

New ophthalmic gene licensed by InSite

Xenova enters telomerase research agreement with Brunel University

Progress at Oxford BioMedica in targeted cancer therapy program

Integrilin stent study halted early due to positive results

Chemotherapy pill cleared to begin clinical trials in Canada

Cogent completes third phase I trial of transdermal patch for treating Alzheimer's disease

Protein Design Labs updates R&D efforts for Q4 and full year 1999

Idec's anticancer agents advance in the clinic

Chinese university scientists design new antiallergic medications

Mechanism of anti-HIV activity of polyanionic dendrimers explored

Ecopipam is able to attenuate the mood-altering and other effects of acute cocaine

Phase III trials to begin for BioCryst's influenza therapy

Insulin sensitizer-anorectic combinations disclosed by Takeda for NIDDM

NCI reports success with 177Lu-CC49 combination therapy in ovarian cancer

Subtype-selective NMDA receptor blockers for neurodegenerative and CNS disorders

German investigators discover new anticoagulant compounds

New cell adhesion inhibitors designed at Celltech

Update on Immunex's rhuCD40L, including latest preclinical data

Chimeric contraceptive vaccines in development at Washington State University

DNA-binding antitumor agents reported by Taiho

Potential new use for imiquimod explored in small clinical study

Sankyo presents new inhibitors of inflammatory cytokine production

Proteasome inhibitor protects against cortical neuronal injury following focal ischemia in SHR

FDA approves Lotronex for IBS in women

Mechanisms underlying deleterious effects of anti-ICAM-1 antibodies in stroke under investigation

Stroke news: Zanaflex reduces spasticity associated with stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026